Dishman Carbogen Amcis Ltd

Net profit of Dishman Carbogen Amcis rose 97.25% to Rs 65.27 crore in the quarter ended September 2025 as against Rs 33.09 crore during the previous quarter ended September 2024. Sales declined 17.29% to Rs 652.65 crore in the quarter ended September 2025 as against Rs 789.04 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales652.65789.04 -17 OPM %22.8118.65 - PBDT114.67117.17 -2 PBT30.5445.08 -32 NP65.2733.09 97 Powered by Capital Market - Live

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 4 November 2025.Powered by Capital Market - Live

Dishman Carbogen Amcis announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live

Dishman Carbogen Amcis announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live

Dishman Carbogen Amcis Ltd rose 4.86% today to trade at Rs 254.7. The BSE Healthcare index is up 0.57% to quote at 44074.27. The index is down 1.71 % over last one month. Among the other constituents of the index, Apollo Hospitals Enterprise Ltd increased 4.33% and Alkem Laboratories Ltd added 3.98% on the day. The BSE Healthcare index went up 7.42 % over last one year compared to the 1.95% surge in benchmark SENSEX. Dishman Carbogen Amcis Ltd has added 1.47% over last one month compared to 1.71% fall in BSE Healthcare index and 2.14% drop in the SENSEX. On the BSE, 4125 shares were traded in the counter so far compared with average daily volumes of 6651 shares in the past one month. The stock hit a record high of Rs 307.8 on 11 Dec 2024. The stock hit a 52-week low of Rs 161.35 on 07 Oct 2024.Powered by Capital Market - Live

Net profit of Dishman Carbogen Amcis reported to Rs 23.41 crore in the quarter ended June 2025 as against net loss of Rs 77.57 crore during the previous quarter ended June 2024. Sales rose 35.18% to Rs 708.05 crore in the quarter ended June 2025 as against Rs 523.78 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales708.05523.78 35 OPM %19.875.53 - PBDT122.67-1.53 LP PBT41.32-72.12 LP NP23.41-77.57 LP Powered by Capital Market - Live

Dishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live

The inspection was conducted from 9 June to 13 June 2025. According to the company's statement, the audit concluded without any observations or the issuance of a Form 483, indicating that the USFDA found no procedural or compliance-related concerns during the inspection. As a result, the company's facilities at Naroda and Bavla in India, along with multiple group facilities in Switzerland and the Netherlands, continue to maintain USFDA approval. The official announcement was made on Saturday, 14 June 2025. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. The company reported a consolidated net profit of Rs 43.09 crore in Q4 March 2025 as against a net loss of Rs 69.92 crore in Q4 March 2024. Revenue from operations rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. The counter declined 2.29% to Rs 273.05 on the BSE. Powered by Capital Market - Live

Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: ' Aarau site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. ' Neuland site: installation of 850-litre reactors and 0.4 m' agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth. Powered by Capital Market - Live

Consolidated net sales rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. Pre-tax profit before exxceptional items stood at Rs 39.45 crore in Q4 FY25 as against pre-tax loss before exceptional items of Rs 46.11 crore in Q4 FY24. For the full year, the company reported net profit of Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore in the year ended March 2024. Net sales rose 3.66% YoY to Rs 2711.50 crore in the year ended March 2025. Pre-tax profit before exceptional items stood at Rs 37.42 crore in FY25 as against pre-tax loss before exceptional items of Rs 116.12 crore in FY24. During the quarter and year ended 31 March 2025, certain subsidiaries discarded some of their inventories, which was not expected to be usable for projects that the company estimated to undertake in near to mid-term. The loss on account of these impairment were Rs 0.77 crore and Rs 7.13 crore respectively for the quarter and year. Further, during the quarter ended 31 March 2025, one of the subsidiaries Carbogen Amcis AG, had impaired expenditure incurred for capex project. The loss on account of this impairment was Rs 10.98 crore for the quarter and the year. The company's consolidated net cash from operating activities stood at Rs 375.23 crore in FY25, lower than Rs 379.43 crore in FY24. Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. Powered by Capital Market - Live